Fingerprints and Cionlabs sign collaboration agreement for developing biometric door locks and embedded applications in India
Fingerprint Cards AB (Fingerprints™) today announced that the company has entered into a collaboration agreement with Cionlabs, an innovative company that delivers cutting-edge engineering solutions tailored to the IoT market. Cionlabs will develop, design, and exclusively incorporate Fingerprints’ biometric sensor, software and algorithm into its extensive product portfolio for smart door locks and IoT products.
The integration of Fingerprints’ technology will enable Cionlabs to enhance the security, flexibility and user-friendliness of the solutions it offers to OEMs, ODMs and suppliers targeting the smart lock and embedded systems markets in India and worldwide, benefitting end users with effortless and convenient access via a simple fingertip touch. OEMs and ODMs seeking to enhance their product portfolios with biometric features will be able to leverage the partnership between Fingerprints and Cionlabs to bring biometric-enabled products to the market faster, while reducing costs compared to in-house development.
Michel Roig, Fingerprints’ President of Payment and Access, comments: “Our dynamic partnership with Cionlabs aims to meet the increasing demand from the smart lock industry for cutting-edge biometric solutions. We are happy to support innovative lock makers and suppliers who value the myriad advantages that smart biometric solutions provide. Together we will provide users with robust, faster and more convenient access control, empowering them to safeguard their assets.“
Dr. Sanjay Ahuja, founder & CEO of Cionlabs, says: “At Cionlabs, innovation is our driving force. We're dedicated to revolutionizing IoT smart products with cutting-edge biometric solutions. Our commitment lies in empowering users to safeguard their assets effortlessly, providing peace of mind in an ever-evolving world. Together with our partner Fingerprints, we will be shaping the future of secure and convenient smart products. Join us on this journey to redefine security and convenience.”
For further information, please contact:
Michel Roig, President Payment & Access
Investor Relations:
+46(0)10-172 00 10, investrel@fingerprints.com
Press:
+46(0)10-172 00 20, press@fingerprints.com
About Fingerprints
Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and seamless universe, where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications, and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information visit our website, read our blog, and follow us on LinkedIn and Twitter. Fingerprints is listed on Nasdaq Stockholm (FING B).
About Cionlabs
Cionlabs is a dynamic and rapidly expanding startup, headquartered in the bustling tech hub of Bengaluru, India. Our core mission is to offer comprehensive product engineering services tailored specifically for Micro, Small, and Medium Enterprises (MSMEs). What sets us apart is our innovative, bottom-up approach to creating cutting-edge solutions. We take immense pride in our "Made-in-India" ethos, where we have developed state-of-the-art IoT modules and an impressive array of smart products designed for home automation. At Cionlabs, we believe that innovation should be accessible to all, and we have diligently crafted a portfolio that not only enhances convenience but also enriches the lives of individuals and families in a tech-driven world. Our commitment to excellence and our passion for transforming the future of technology make Cionlabs a trusted partner for businesses seeking to unlock the potential of the Internet of Things and home automation.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote
Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release
Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla
Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release
29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the
Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel